IRVINE, Calif. - TelAve -- xBxBio today announced that it has filed a U.S. provisional patent application relating to xBxBio's Virtual Heart™, marking an important milestone in the company's intellectual-property and cardiovascular-technology development strategy.

xBxBio's Virtual Heart™ is being developed as part of the company's broader vision for Connected Cardiovascular Intelligence™. Its long-term purpose is to support a more patient-centered and longitudinal understanding of cardiovascular information while keeping clinicians at the center of assessment, interpretation, and decision-making.

The provisional patent application establishes an early filing milestone while allowing xBxBio to continue its research, engineering, scientific evaluation, validation planning, and intellectual-property development.

More on TelAve News

• Woodside Rehab & Nursing Enters a New Era of Clinical Excellence and Growth
• Thar Process Partners with French Leader ExtrateX to Bring Prep to Process-Scale SFC to Europe
• iPhone 18 Pro Genuine Cowhide Case | Vintage iPhone Case | Distressed iPhone Case
• Port St. Lucie REALTOR® Irene Pernice Earns SFR® Certification
• AMR and UAS Take the Stage at WorldSkills Shanghai 2026

To protect its confidential and proprietary information, xBxBio is not publicly disclosing the invention's technical architecture, algorithms, computational methods, model designs, implementation details, development materials, patent claims, or other enabling information.

"Filing this provisional patent application is an important step in protecting the innovation associated with xBxBio's Virtual Heart™," said an xBxBio spokesperson. "Our objective is to advance patient-specific cardiovascular intelligence responsibly, with scientific rigor, clinical relevance, traceability, human oversight, and respect for the physician-patient relationship."

xBxBio's work is guided by the principle that cardiovascular information should be understood in the context of the individual patient and evaluated across time. The company's ultimate purpose is to help clinicians consider patient-specific evidence as they develop individualized recommendations.

The company will continue protecting its intellectual property while sharing appropriate non-confidential information about its scientific principles, governance framework, validation approach, and development progress.

More on TelAve News

• Biophysical Therapeutics brings longevity science to skincare with its new IF1 brand
• JoCa's Echoes of Haworth Sells Out on Opening Night in Mexico City; Artist Heads to San Luis Potosí and Miami Art Week
• Home2 Suites by Hilton Lee's Summit, MO Opens to Guests
• Shanghai Chengwei Semiconductor Equipment Launches High Precision Laboratory Central Gas Supply System
• Your Local Pro Expands National Service Network to 273+ Locations Across Plumbing, Cleaning, Landscaping and Hydrovac

A provisional patent application is an initial filing and is not an issued patent. Filing does not mean that the invention has been examined, approved, or granted patent protection by the United States Patent and Trademark Office.

xBxBio's Virtual Heart™ remains under development. It has not been authorized or cleared for clinical use and is not intended to replace professional medical judgment.

About xBxBio

xBxBio is developing Connected Cardiovascular Intelligence™ to help bring fragmented cardiovascular information into a more connected, contextual, longitudinal, and clinically meaningful environment.

The company focuses on cardiovascular informatics, multimodal information, clinical artificial intelligence, healthcare interoperability, data integrity, provenance, validation, governance, and responsible human oversight.

xBxBio views artificial intelligence as a means of strengthening clinical intelligence—not replacing accountable healthcare professionals.

Learn more about xBxBio:
https://xbxbio.com